TSVT: 2seventy Bio Net earnings per share (EPS TTM)

Public company logo of 2seventy bio Inc. (TSVT)

2seventy bio, Inc. (TSVT) is currently undergoing a qualitative transformation, focusing on the rollout of Abecma and the optimization of its scientific portfolio. The TTM EPS annual snapshot helps filter out market noise, while the -0.10 value reflects the metric's balance. The company's strategy, spun off from bluebird bio, is based on treating lymphomas and myeloma. The development of CAR-T products relies on synergy with major pharma partners to accelerate the time-to-market for drugs.

TSVT (2seventy bio, Inc.) Net earnings per one share for the last twelve months history from 07/04/2022 to 05/24/2025

2seventy bio Inc. - analytical breakdowns and key metrics (TSVT)

- share price and expert price forecast:
Stock Quotes 2seventy bio, Inc.|TSVT - Fair Value Consensus
- market capitalization information:
Market Capitalization 2seventy bio, Inc.|TSVT - Real Price to Acquire Entire Company
- business book valuation details:
Book Value per Share 2seventy bio|TSVT - Total Stockholders' Equity|Market Value to Book Value Ratio 2seventybio.com|TSVT - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity 2seventy bio, Inc.|TSVT - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio 2seventy Bio|TSVT - Aggregate Debt Obligations|Debts to Book Capitalization 2seventy bio, Inc.|TSVT - Long-Term Indebtedness|Company Short-Term Debts 2seventy bio|Quick Liquidity 2seventybio.com
- net income and valuation multiples indicators:
TSVT - Company Profit|Projected Future Earnings 2seventy bio, Inc.|TSVT - Market Cap to Earnings|Projected Price to Earnings 2seventy bio|TSVT - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio 2seventy bio, Inc.|TSVT - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) 2seventy bio|TSVT - Earnings per share for the trailing year|Quarterly EPS earnings growth 2seventybio.com|TSVT - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year 2seventy bio, Inc.
General company analysis:2seventy bio, Inc. (TSVT)
Mass-produced product of 2seventy bio, Inc

2seventy bio, Inc. (TSVT) is strengthening its position through the commercialization of Abecma therapy. The calculated TTM EPS digitizes this efficiency by allocating total net income per common share. This metric captures actual KPI performance, eliminating the subjectivity of corporate forecasts. It reflects the real operational flow from royalties, smoothing out reporting time lags. Analyzing the 12-month rolling income per share allows for an objective assessment of the business development trajectory.

Analysis of competing companies

LEGN: Net earnings per share for the last 12 months|Earnings per share for the trailing year SANA (sana.com)|AUTL: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Allogene Therapeutics, Inc.|RNAC (Cartesian Therapeutics Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Cellectis Biotherapeutics CLLS|Earnings per share for the last twelve months Caribou Biosciences (CRBU)|Earnings per share for the last twelve months TIL (instilbio.com)|Earnings per share for the last twelve months Genenta Science GNTA|Century Tx - Earnings per share for the last twelve months|JSPR: Net earnings per share for the last 12 months|Earnings per share for the trailing year SNTI (Senti Biosciences, Inc.)|ADAP: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year CERo Therapeutics Holdings CERO|TCRT (Alaunos Therapeutics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Achilles Tx ACHL|Earnings per share for the last twelve months Cargo Therapeutics (CRGX)|Poseida Corp - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) GRCL (Gracell Biotechnologies)